Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

Inclusion Criteria: * Patients enrolled in hospice care at home * Age ≥ 21 years. * Any terminal illness with respect of exclusion criteria * Palliative Performance Scale (PPS) ≥ 50 % (see Appendix A) * Moderate-to-severe demoralization as measured by Demoralization Scale-II ≥ 8 * Significant other or other caregiver present at home the night of study drug administration * No driving for 24 hours following study drug administration. * English proficiency * Ability to understand and the willingness to sign a written informed consent document. * Psilocybin is very likely to have no genotoxic effects. One study that directly focused on the mutagenic potential of psilocybin did not found this type of toxicity. However, due to the lack of clinical and non-clinical studies on the effects of psilocybin on the developing human fetus, women and men of child-bearing potential and who are sexually active must agree to use an acceptable contraceptive method (hormonal or barrier method of birth control; abstinence) throughout their participation in the study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of psilocybin administration. Exclusion Criteria: * Current General Inpatient (GIP) hos…